NASDAQ: TXMDTherapeuticsmd Inc Stock
$1.00-0.01 (-0.99%)
Updated Apr 21, 2025
TXMD Price
$1.00
Fair Value Price
N/A
Market Cap
$11.53M
52 Week Low
$0.70
52 Week High
$2.44
P/E
-5.24x
P/B
0.42x
P/S
5.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.76M
Earnings
-$2.18M
Gross Margin
100%
Operating Margin
-125.61%
Profit Margin
-123.9%
Debt to Equity
0.42
Operating Cash Flow
$732k
Beta
1.17
Next Earnings
May 8, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TXMD Overview
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TXMD's potential to beat the market
- TXMD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
TXMD
RankedUnranked of 54
RankedUnranked of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.13 | A | |
| $13.89 | A | |
| $30.29 | A |
Be the first to know about important TXMD news, forecast changes, insider trades & much more!
TXMD News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TXMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TXMD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TXMD is good value based on its book value relative to its share price (0.42x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.98x)
P/B vs Industry Valuation
TXMD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TXMD due diligence checks available for Premium users.
Valuation
TXMD fair value
Fair Value of TXMD stock based on Discounted Cash Flow (DCF)
Price
$1.00
Fair Value
-$0.04
Undervalued by
2,487.58%
TXMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TXMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.24x
Industry
20.59x
Market
27.14x
TXMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.42x
Industry
1.98x
TXMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TXMD's financial health
Profit margin
Revenue
$667.0k
Net Income
$252.0k
Profit Margin
37.8%
TXMD's Earnings (EBIT) of -$2.21M... subscribe to Premium to read more.
Interest Coverage Financials
TXMD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$38.8M
Liabilities
$11.5M
Debt to equity
0.42
TXMD's short-term assets ($12.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TXMD's short-term assets ($12.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TXMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TXMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.0k
Investing
$0.0
Financing
$0.0
TXMD's operating cash flow ($732.00k)... subscribe to Premium to read more.
Debt Coverage Financials
TXMD vs Pharmaceutical Stocks
Therapeuticsmd Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.